Assessment of Cancer Concerns at the End of Treatment (ACE)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer(BC) Survivors
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Enrollment
- 332
- Locations
- 1
- Primary Endpoint
- Completion of Questionnaire
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate provider satisfaction following delivery of an electronic health record (HER)/EPIC summary of these PROs. Secondary aims will estimate differences in referral to available services between those providers exposed to the PRO summary and historical controls. BC survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (EOT)/survivorship focused visit will be the focus of this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with invasive, non-metastatic BC (Stage I, II, or III) without hematogenous or distant metastases
- •Have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). May still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase inhibitors).
- •Within 1 year of completing primary treatment
- •Scheduled for an EOT visit
- •Age 18 years or older
- •Can understand written English
- •Have internet access and a working email address
Exclusion Criteria
- •Diagnosed with non-invasive (Stage 0/DCIS) or metastatic (Stage IV) cancer or hematogenous or distant metastatic disease
- •No working email address -
Outcomes
Primary Outcomes
Completion of Questionnaire
Time Frame: 2 years